Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Caitlin Tucker"'
Publikováno v:
HortTechnology, Vol 33, Iss 4 (2023)
Grafted and ungrafted ‘Primo Red’ tomato (Solanum lycopersicum) transplants were planted at 16-, 20-, and 24-inch spacing in a commercial high tunnel in central New York, USA, to compare yields. ‘Primo Red’ scions were grafted onto ‘Maxifor
Externí odkaz:
https://doaj.org/article/12fce0b0285a427a9ddbc9aa3c9c6431
Publikováno v:
Journal of food protection. 85(4)
The Produce Safety Rule of the Food Safety Modernization Act (FSMA) sets forth minimum standards for fruit and vegetable production in the United States. One provision states that growers must not harvest dropped produce because damage or ground cont
Autor:
Shireen Vali, Christopher R. Cogle, Jan S. Moreb, Glenda G. Anderson, Vindhya Vijay, Neeraj Kumar Singh, John W. Hiemenz, Jatinder K. Lamba, Cesia Salan, Jack W. Hsu, Arati Khanna-Gupta, William B. Slayton, Kimberly E. Hawkins, Elizabeth Wise, Amy Meacham, Nosha Farhadfar, Christina Cline, Paul Castillo, Biljana Horn, Leylah Drusbosky, Taher Abbasi, Maxim Norkin, S. Radhakrishnan, Helen Leather, Caitlin Tucker, Yashaswini S Ullal, Madeleine Turcotte, Huzaifa Sikora, Prashant Ramachandran Nair, Leslie Pettiford, John R. Wingard, Hemant S. Murthy, Subharup Guha, Charlie C. Kim, Randy A. Brown, Anay Talawdekar
Publikováno v:
Blood Advances. 3:1837-1847
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential. To address this,
Autor:
John R. Wingard, Caitlin Tucker, Shireen Vali, Kabya Basu, Kimberly E. Hawkins, Leylah Drusbosky, Randy A. Brown, Amjad Husain, John W. Hiemenz, Jack W. Hsu, Ansu Kumar, Maxim Norkin, Chandan Kumar, Neeraj Kumar Singh, Christopher R. Cogle, Taher Abbasi
Publikováno v:
Cancer Research. 77:CT085-CT085
Hypomethylating agents (HMAs) (azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Despite their widespread use, HMAs fail in
Autor:
Maxim Norkin, Jack W. Hsu, Elizabeth Wise, John W. Hiemenz, Caitlin Tucker, Amjad Husain, John R. Wingard, Ansu Kumar, Leylah Drusbosky, Neeraj Kumar Singh, Kabya Basu, Shireen Vali, Fei Zou, Chandan Kumar, Taher Abbasi, Christopher R. Cogle, Randy A. Brown
Publikováno v:
Blood. 128:594-594
Background: Hypomethylating agents (HMAs) (e.g., azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used in the treatment of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Despite their